Comparative Pharmacology
Head-to-head clinical analysis: DEXAIR versus FLOVENT DISKUS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAIR versus FLOVENT DISKUS 250.
DEXAIR vs FLOVENT DISKUS 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEXAIR (dexamethasone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., cytokines, prostaglandins). It also inhibits leukocyte infiltration and reduces capillary permeability.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Inhalation: 2 inhalations (80 mcg each) twice daily, maximum 640 mcg/day.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
None Documented
None Documented
Terminal elimination half-life: 3.0-4.5 hours in adults with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Renal (urinary): ~65-75% as unchanged drug and metabolites; biliary/fecal: ~20-30% as metabolites; less than 10% unchanged in bile.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Category C
Category C
Corticosteroid
Corticosteroid